retatrutide phase 2 trial Great news again!!! A of (Triple–Hormone-Receptor Agonist) for obesity. At 48 wks the median body weight loss was 24.2% and >5%, >10% and >15% had occurred in 100% Phase 2 Trial of Retatrutide
Description
This extra receptor interaction enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss
This study highlights the importance of considering both the benefits and drawbacks of using GLP-1 agonists
Even electrolyte drinks may benefit from the GLP-1 boom
Approval is not expected until mid-2026 or 2027 at the earliest
It also releases endorphins, serotonin and dopamine
